PR93866

CHENGDU, China, Dec. 24, 2021 /PRNewswire=KYODO JBN/ --

WestVac BioPharma Co., Ltd. has achieved a significant progress in the second

generation COVID-19 vaccine against the Omicron mutant strain.

The vaccine belongs to the latest fifth generation vaccine technology,

targeting the S-RBD protein of the COVID-19 mutant strain, the trimer subunit

vaccine antigen is precisely designed based on the structure. The large-scale

production of vaccines adopts internationally advanced insect cell production

technology and coordinates with international novel vaccine adjuvants. The

vaccine can induce the production of high titers of neutralizing antibodies

upon immunizing animals such as mice or monkeys. The neutralizing antibodies

against the Omicron variant strain can reach a level of ten thousands (when

blood is diluted 10,000 times, it still has the ability to block the virus from

infecting cells). It was previously discovered that the vaccine has a level of

ten thousands neutralizing antibodies that completely inhibits Brazilian

strains, South African strains, Delta strains and other mutant strains of

Euvirus, suggesting that the vaccine is a universal COVID-19 vaccine against

multiple mutant strains, and it is also the first COVID-19 vaccine announced

internationally that has high titers of neutralizing antibodies against

Omicron. Animal experiments conducted with sequential vaccination of different

types of COVID-19 vaccines showed that two doses of mRNA/inactivated vaccine or

one dose of adenovirus vaccine, followed by the vaccine, rapidly activated the

immune response and produced higher protective neutralizing antibodies than the

same type of vaccine. The vaccine has completed process research and

large-scale preparation. The production process is stable and it has been

certified by the National Institutes for Food and Drug Control; the

pharmacodynamic research on the immunogenicity and protection of mice, rats,

and monkeys, as well as pre-clinical safety evaluation has been completed; it

is expected to enter clinical trials in early 2022.

WestVac Biopharma is a international leading vaccine and immunothreapy

platform. It is listed as a unicorn company in 2021. WestVac has GMP production

workshops with an annual production of 600 million doses, and obtained the

"Drug Production License" issued by the the local medical products

administration. The company has mature insect cell expression, mRNA vaccine,

novel adjuvant, bacterial vaccine and tumor vaccine and immunotherapy

platforms, and has 21 pipelines. A nasal spray recombinant COVID-19 vaccine

against variants is also being developed. Its convenience will boost

vaccination worldwide.

SOURCE  WestVac Biopharma Co.,Ltd.

Image Attachments Links:

   Link: http://asianetnews.net/view-attachment?attach-id=411834